Goldman Sachs Reiterates Neutral Rating on Ionis Pharmaceuticals, Inc. (IONS)

Market Context

Ionis Pharmaceuticals, Inc. operates in the Healthcare sector. The stock currently trades at $78.34 with a market capitalization of $12.6B. The stock has gained 98.3% over the past 52 weeks.

Analyst coverage from Goldman Sachs provides professional research and price targets that many institutional investors reference when making allocation decisions. The consensus of analyst opinions — along with the range of price targets — helps frame market expectations for Ionis Pharmaceuticals, Inc..

Analyst ratings and price targets are one input among many for investment decisions. Historical studies show that consensus analyst recommendations have mixed predictive power on their own, but significant changes in consensus — such as multiple upgrades or downgrades in a short period — can be more meaningful signals.

Recent Analyst Activity for Ionis Pharmaceuticals, Inc.

Among the 10 most recent ratings: 9 Buy, 1 Hold, 0 Sell.

Date	Firm	Rating	Price Target
Jun 25, 2026	Leerink Partners	Outperform	N/A
Jun 25, 2026	Goldman Sachs	Neutral	N/A
Jun 25, 2026	HC Wainwright & Co.	Buy	N/A
Jun 17, 2026	Leerink Partners	Outperform	N/A
Jun 15, 2026	TD Cowen	Buy	N/A

Related Tools: Analyst Ratings Dashboard | View IONS Stock Page